TP53 and colorectal carcinoma: Based on the whole-exome sequencing of the three pairs of CRC lines, resistance to cisplatin-based chemotherapy was also positively correlated with TP53 mutation burden, consistent with a previous study (Bergamaschi et al., 2003).